These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17329683)

  • 1. Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging.
    Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Klein M; Bares R; Claussen CD; Eschmann SM
    Br J Radiol; 2007 Jun; 80(954):437-45. PubMed ID: 17329683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
    Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
    J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.
    Pfannenberg AC; Aschoff P; Brechtel K; Müller M; Bares R; Paulsen F; Scheiderbauer J; Friedel G; Claussen CD; Eschmann SM
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):36-44. PubMed ID: 16896664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
    Bar-Shalom R; Yefremov N; Guralnik L; Gaitini D; Frenkel A; Kuten A; Altman H; Keidar Z; Israel O
    J Nucl Med; 2003 Aug; 44(8):1200-9. PubMed ID: 12902408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients.
    Berthelsen AK; Holm S; Loft A; Klausen TL; Andersen F; Højgaard L
    Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1167-75. PubMed ID: 15909196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error?
    Yau YY; Chan WS; Tam YM; Vernon P; Wong S; Coel M; Chu SK
    J Nucl Med; 2005 Feb; 46(2):283-91. PubMed ID: 15695788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT.
    Froeling V; Röttgen R; Collettini F; Rothe J; Hamm B; Brenner W; Schreiter N
    Q J Nucl Med Mol Imaging; 2014 Sep; 58(3):310-8. PubMed ID: 25265251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective interactive rigid fusion of (18)F-FDG-PET and CT. Additional diagnostic information in melanoma patients.
    Römer W; Nömayr A; Greess H; Fiedler E; Platsch G; Schuler-Thurner B; Pfahlberg A; Hothorn T; Schuler G; Hornegger J; Bautz W; Kuwert T
    Nuklearmedizin; 2006; 45(2):88-95. PubMed ID: 16547570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT.
    Beyer T; Antoch G; Bockisch A; Stattaus J
    J Nucl Med; 2005 Mar; 46(3):429-35. PubMed ID: 15750155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
    Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.
    Morbelli S; Conzi R; Campus C; Cittadini G; Bossert I; Massollo M; Fornarini G; Calamia I; Marini C; Fiz F; Ghersi C; Derchi LE; Sambuceti G
    Cancer Imaging; 2014 Apr; 14(1):10. PubMed ID: 25609564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.